Highly diluted medication reduces parasitemia and improves experimental infection evolution by Trypanosoma cruzi

详细信息    查看全文

• 作者：Denise Lessa Aleixo (1)
  Fabiana Nabarro Ferraz (1)
  érika Cristina Ferreira (1)
  Marta de Lana (2)
  M?nica Lúcia Gomes (1)
  Benício Alves de Abreu Filho (3)
  Silvana Marques de Araújo (1)
  
• 关键词：Biotherapy ; Mice infection ; Parasitological evaluation ; Clinical evaluation ; Prepatent period
• 刊名：BMC Research Notes
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：5
• 期：1
• 全文大小：314KB
• 参考文献：1. Lyrio C: / Nosódios Bioterápicos: Repertório. C. Lyrio, Rio de Janeiro; 2002.
  2. Bonamin LV: Teorias Interpretativas sobre ultradilui??es: Ilustra??es Experimentais. / Cultura Homeopática 2006, 16:6-7.
  3. Bellavite P, Ortolani R, Pontarollo F, Pitari G, Conforti A: Immunology and Homeopathy. 5. The Rationale of the ‘Simile- / Evidence-Based Complementary and Alternative Medicine 2007,4(2):149-63. CrossRef
  4. Sandri PF, Falkowski GJS, Nascimento Júnior AD, Spack M, Moreira NM, Toledo MJO, Abreu Filho B, Gabriel M, Araújo SM: Biotherapic of Trypanosoma cruzi 17x controlled histopathological alterations in mice infected by this protozoon. / International Journal of High Dilution Research 2011,10(36):119-2.
  5. Thompson EA: Homeopathy and menopause. / J Br Menopause Soc 2002,8(4):151-54.
  6. Vetoshkina TV, Fomina TI: Effects of homeopathic preparations on the liver in rats with acute and chronic toxic hepatitis. / Bull Exp Biol Med 2003,135(1):85-7. CrossRef
  7. Brack A, Strube J, Stoltz P, Decker H: Effects of ultrahigh dilutions of 3,5-dichlorophenol on the luminescence of the bacterium Vibrio fischeri. / Biochemical, Biophysical Acta 2003,1621(3):253-60. CrossRef
  8. Brasília DF: / Farmacopéia Homeopática Brasileira. 3rd edition. Ed. Agência Nacional de Vigilancia Sanitária (ANVISA), Brasília DF; 2011.
  9. Almeida LR: / Efeitos de medicamentos Homeopáticos e Bioterápicos em Camundongos experimentalmente infectados por Trypanosoma evansi (STEEL, 1885) BALBIANI, 1988 e Trypanosoma cruzi CHAGAS, 1909. Tese Doutorado em Ciências Veterinárias -Instituto de Veterinária/Universidade Federal Rural do Rio de Janeiro, Seropédica; 2007:68.
  10. Bonamin LV, Lagache A, Bastide M: Research on Ultra-dilutions and the Theory of Corporeal Signifiers: The Follow Up. In / Signals and Images: Contributions and contradictions about high dilution research. Ed. Springer, S?o Paulo: Bonamin LV; 2008.
  11. Coura JR, Dias JC: Epidemiology, control and surveillance of Chagas disease - 100 years after its discovery. / Memórias do Instituto Oswaldo Cruz 2009,104(Suppl. I):31-0.
  12. Silva LHP, Nussenzweig V: Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. / Folia Clínica Biologia S?o Paulo 1953, 20:191-01.
  13. Pinto PLS, Takami R, Nunes EV, Guilherme CS, Oliveira JOC, Gama-Rodrigues J, Okumura M: Life cycle of Trypanosoma cruzi (y strain) in mice. / Revista do Hospital das Clínicas 1999, 54:141-46. CrossRef
  14. Coura JR, Castro SL: A critical review on Chagas Disease Chemotherapy. / Memórias do Instituto Oswaldo Cruz 2002,97(1):3-4. CrossRef
  15. Higuchi MD: Endomyocardial biopsy in Chagas' heart disease: pathogenetic contributions. / Sao Paulo Med J 1995, 113:821-25. CrossRef
  16. Tafuri WL: Patogenia da doen?a de chagas. / Rev Inst Med Trop S?o Paulo 1987,29(4):194-99. CrossRef
  17. Desquesnes M, Lana M: Veterinary Aspects and Experimental Studies. In / American Trypanosomiasis Chagas Disease: one hundread year of research. Edited by: Telleria J, Tibayrenc M. Elsevier Inc., London; 2010.
  18. Sandri PF: / Influência da idade sobre os efeitos do bioterápico 17 dH na infec??o de camundongos pelo Trypanosoma cruzi. Disserta??o (Mestrado em Biociências Aplicada a Farmácia). Universidade Estadual de Maringá, S?o Paulo, SP; 2010:79.
  19. Teixeira MZ: Possíveis contribui??es do modelo homeopático à humaniza??o da forma??o médica. / Revista Brasileira de Educa??o Médica 2009, 33:454-63. CrossRef
  20. Dodoo D, Omer FM, Todd J, Akanmori BD, Koram KA, Riley EM: Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. / Journal of Infectious Disease 2002,185(7):971-79. CrossRef
  21. Clark IA, Alleva LM, Mills AC, Cowden WB: Pathogenesis of malaria and clinically similar conditions. / Clin Microbiol Rev 2004,17(3):509-39. CrossRef
  22. Jones TR, Narum DL, Gozalo AS, Aguiar J, Fuhrmann SR, Liang H, Haynes JD, Moch JK, Lucas C, Luu T: Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. / Journal of Infectious Disease. 2001,183(2):303-12. CrossRef
  23. Wickramasinghe SN, Abdalla SH: Blood and bone marrow changes in malaria. / Baillieres Best Practice and Research Clinical Haematology 2000,13(2):277-99. CrossRef
  24. Claudia TM, M?nica LG, Aline VM, Silvana MA, Maria TB, Olindo AM, Marta L, Max JOT: Usefulness of the polymerase chain reaction for monitoring cure of mice infected with different Trypanosoma cruzi clonal genotypes following treatment with benznidazole. / Exp Parasitol 2008,120(1):45-9. CrossRef
  25. Telleria J, Tibayrenc M: / American Trypanosomiasis Chagas Disease: one hundread year of research. Elsevier Inc, London; 2010.
  26. Araújo-Jorge TC: Modelos experimentais para o estudo in vivo da doen?a de Chagas: Camundongo. / Doen?a de Chagas: Manual de experimenta??o animal. Fiocruz 2000.
  27. Ferraz FN, Simoni GK, Nascimento AD, Melo CS, Aleixo DL, Gomes ML, Spaki M, Araújo SM: Different forms of administration of biotherapy 7dH in mice experimentally infected by Trypanosoma cruzi produce different effects. / Homeopathy 2011, 100:237-43. CrossRef
  28. Carvalheiro JR, Collares EF: Estudos sobre o comportamento em camundongos de uma amostra altamente virulenta de Trypanosoma cruzi (Amostra Y), após passagem em triatomíneos, ratos e culturas. / Rev Bras Biol 1965, 25:169-5.
  29. Billotti C, Ferraz FN, Spack M, Nascimento Júnior AD, Panza S, Alvares AA, Gomes ML, Toledo MJ, Martinichen JC, Araújo SM: Parametros hematológicos em camundongos infectados pelo Trypanosoma cruzi e tratados com bioterápicos. / Brazilian Homeopathic Journal 2009, 11:9-0.
  30. Sandri PF, Falkowski GJS, Hernandes L, Dalalio MO, Aleixo DL, Gomes ML, Anélio DN, Moliterno RA, Araujo SM: Biotherapic of Trypanosoma cruzi 17d increases apoptosis in experimentally infected mice. / Proceedings of the XXV GIRI Symposium and VIII CBFH on International Journal of High Dilution Research 2011, 2011:119-24.
  31. BRASIL Ministério da Saúde: / RESOLU??O DA DIRETORIA COLEGIADA - RDC N° 67. Diário Oficial da Uni?o, Brasília (DF), Diário Oficial da Uni?o, Brasília (DF); 2007. 8 de outubro de 2007
  32. Brener Z: Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. / Rev Inst Med Trop S?o Paulo 1962, 4:189-96.
  33. Silva DR, Castro SL, Alves MCS, Batista WS, Oliveira GM: Acute experimental Trypanosoma cruzi infection: establishing a murine model that utilizes non-invasive measurements of disease parameters. / Memórias do Instituto Oswaldo Cruz 2012,107(2):211-16.
  
• 作者单位：Denise Lessa Aleixo (1)
  Fabiana Nabarro Ferraz (1)
  érika Cristina Ferreira (1)
  Marta de Lana (2)
  M?nica Lúcia Gomes (1)
  Benício Alves de Abreu Filho (3)
  Silvana Marques de Araújo (1)
  
  1. Laboratory of Parasitology, Universidade Estadual de Maringá, Maringá, PR, Brazil
  2. Laboratory of Parasitology, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil
  3. Laboratory of Microbiology, Universidade Estadual de Maringá, Maringá, PR, Brazil
  

文摘

Background There is no published information about the use of different protocols to administer a highly diluted medication. Evaluate the effect of different protocols for treatment with biotherapic T. cruzi 17 dH (BIOT Tc17dH) on clinical/parasitological evolution of mice infected with T. cruzi-Y strain. Methods A blind, randomized controlled trial was performed twice, using 60 28-day-old male Swiss mice infected with T. cruzi-Y strain, in five treatment groups: CI - treated with a 7% ethanol-water solution, diluted in water (10 μL/mL) ad libitum; BIOT PI - treated with BIOT Tc17dH in water (10 μL/mL) ad libitum during a period that started on the day of infection; BIOT 4DI - treated with BIOT Tc17dH in water (10 μL/mL) ad libitum beginning on the 4th day of infection; BIOT 4-5- - treated with BIOT Tc17dH by gavage (0.2?mL/ animal/day) on the 4th, 5th and 6th days after infection; BIOT 7-8- - treated with BIOT Tc17dH by gavage (0.2?mL/ animal/day) on the 7th, 8th and 9th days after infection. We evaluated: parasitemia; total parasitemia (Ptotal); maximum peak of parasites; prepatent period (PPP) - time from infection to detection of the parasite in blood; patent period (PP) - period when the parasitemia can be detected in blood; clinical aspects; and mortality. Results Parasitological parameters in the BIOTPI and mainly in the BIOT4PI group showed better evolution of the infection compared to the control group (CI), with lower Ptotal, lower maximum peak of parasites, higher PPP, lower PP and longer survival times. These animals showed stable body temperature and higher weight gain and water consumption, with more animals having normal-appearing fur for longer periods. In contrast, groups BIOT4-5- and BIOT7-8- showed worse evolution of the infection compared to the control group, considering both parasitological and clinical parameters. The correlation analysis combined with the other data from this study indicated that the prepatent period is the best parameter to evaluate the effect of a medication in this model. Conclusions The BIOT4DI group showed the best clinical and parasitological evolution, with lower parasitemia and a trend toward lower mortality and a longer survival period. The prepatent period was the best parameter to evaluate the effect of a medication in this model.